Genelux (GNLX) Competitors $3.54 +0.14 (+3.96%) As of 12:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. SLDB, OPT, KURA, RAPP, RZLT, ORKA, PGEN, TERN, SIGA, and PRTCShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Solid Biosciences (SLDB), Opthea (OPT), Kura Oncology (KURA), Rapport Therapeutics (RAPP), Rezolute (RZLT), Oruka Therapeutics (ORKA), Precigen (PGEN), Terns Pharmaceuticals (TERN), Siga Technologies (SIGA), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Its Competitors Solid Biosciences Opthea Kura Oncology Rapport Therapeutics Rezolute Oruka Therapeutics Precigen Terns Pharmaceuticals Siga Technologies PureTech Health Solid Biosciences (NASDAQ:SLDB) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations. Does the media favor SLDB or GNLX? In the previous week, Solid Biosciences had 22 more articles in the media than Genelux. MarketBeat recorded 24 mentions for Solid Biosciences and 2 mentions for Genelux. Genelux's average media sentiment score of 1.38 beat Solid Biosciences' score of 0.58 indicating that Genelux is being referred to more favorably in the news media. Company Overall Sentiment Solid Biosciences Positive Genelux Positive Do analysts rate SLDB or GNLX? Solid Biosciences currently has a consensus price target of $15.00, indicating a potential upside of 145.10%. Genelux has a consensus price target of $17.75, indicating a potential upside of 400.71%. Given Genelux's stronger consensus rating and higher possible upside, analysts clearly believe Genelux is more favorable than Solid Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has preferable valuation and earnings, SLDB or GNLX? Genelux has lower revenue, but higher earnings than Solid Biosciences. Genelux is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolid Biosciences$8.09M58.91-$124.70M-$2.99-2.05Genelux$10K13,389.47-$29.87M-$0.86-4.12 Is SLDB or GNLX more profitable? Solid Biosciences' return on equity of -69.70% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets Solid BiosciencesN/A -69.70% -56.74% Genelux N/A -107.47%-83.14% Do insiders and institutionals have more ownership in SLDB or GNLX? 81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 1.9% of Solid Biosciences shares are owned by company insiders. Comparatively, 8.8% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, SLDB or GNLX? Solid Biosciences has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, Genelux has a beta of -0.32, indicating that its share price is 132% less volatile than the S&P 500. SummarySolid Biosciences beats Genelux on 9 of the 16 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$133.90M$3.12B$5.67B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-4.1220.6830.4025.56Price / Sales13,389.47362.39463.46115.41Price / CashN/A43.0338.2159.48Price / Book5.638.618.996.13Net Income-$29.87M-$54.65M$3.25B$264.98M7 Day Performance12.54%6.00%4.59%2.67%1 Month Performance15.10%8.91%6.61%3.10%1 Year Performance66.43%13.77%30.19%24.93% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.8828 of 5 stars$3.55+4.0%$17.75+400.7%+63.2%$133.90M$10K-4.1210News CoveragePositive NewsAnalyst RevisionSLDBSolid Biosciences3.5215 of 5 stars$6.82-0.1%$15.10+121.4%-26.1%$529.43M$8.09M-2.28100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionOPTOpthea0.4103 of 5 stars$3.41+7.2%$1.33-60.9%+47.6%$524.84M$120K0.008News CoverageGap UpHigh Trading VolumeKURAKura Oncology4.0182 of 5 stars$6.32+5.0%$24.50+287.7%-65.3%$521.18M$53.88M-3.01130News CoverageGap UpRAPPRapport Therapeutics1.7749 of 5 stars$14.04-0.8%$28.00+99.4%-26.8%$516.44MN/A-4.07N/AAnalyst RevisionRZLTRezolute3.2151 of 5 stars$5.90+0.5%$11.83+100.6%+48.5%$510.67MN/A-5.1340Positive NewsORKAOruka Therapeutics2.9762 of 5 stars$14.30+5.1%$40.38+182.3%N/A$509.19MN/A-3.17N/ANews CoverageEarnings ReportAnalyst ForecastAnalyst RevisionPGENPrecigen3.9948 of 5 stars$1.76+5.4%$6.00+240.9%+65.2%$492.95M$3.92M-3.14190Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap UpTERNTerns Pharmaceuticals4.0365 of 5 stars$5.75+5.1%$15.63+171.7%+4.3%$477.73MN/A-5.2840SIGASiga Technologies1.8787 of 5 stars$6.65+2.9%N/A-28.3%$461.51M$138.72M9.9340PRTCPureTech Health2.8012 of 5 stars$18.88-1.1%$45.00+138.3%-24.7%$458.62M$4.83M0.00100News CoverageShort Interest ↓Gap Up Related Companies and Tools Related Companies Solid Biosciences Alternatives Opthea Alternatives Kura Oncology Alternatives Rapport Therapeutics Alternatives Rezolute Alternatives Oruka Therapeutics Alternatives Precigen Alternatives Terns Pharmaceuticals Alternatives Siga Technologies Alternatives PureTech Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access